Fluorescein

Identification

Summary

Fluorescein is a dye used in angiography or angioscopy of the iris and retina.

Brand Names
Ak-fluor, Altafluor, Diofluor, Fluorescite, Fluress
Generic Name
Fluorescein
DrugBank Accession Number
DB00693
Background

A phthalic indicator dye that appears yellow-green in normal tear film and bright green in a more alkaline medium, such as the aqueous humor, and is used therapeutically as a diagnostic aid in corneal injuries and corneal trauma. It has been approved by FDA for use in externally applied drugs and cosmetics. (From Merck Index, 12th ed; American Medical Association Drug Evaluations; 1995, p2275)

Type
Small Molecule
Groups
Approved
Structure
Weight
Average: 332.3063
Monoisotopic: 332.068473494
Chemical Formula
C20H12O5
Synonyms
  • 3,6-fluorandiol
  • 3',6'-dihydroxyfluoran
  • 9-(o-carboxyphenyl)-6-hydroxy-3-isoxanthenone
  • 9-(o-carboxyphenyl)-6-hydroxy-3H-xanthen-3-one
  • C.I. Solvent Yellow 94
  • D and C Yellow No. 7
  • D&C Yellow No. 7
  • Fluorescein
  • Fluoresceina
  • Fluoresceína
  • Fluoresceine
  • Fluoreszein
  • Japan Yellow 201
  • Resorcinolphthalein
  • Solvent Yellow 94
  • Yellow fluorescein
External IDs
  • CI 45350:1

Pharmacology

Indication

For diagnostic imaging. Primarily indicated in diagnostic fluorescein angiography or angioscopy of the fundus and of the iris vasculature.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Used in combination to managePeritoneal dialysisCombination Product in combination with: Magnesium chloride (DB09407), Calcium chloride (DB01164), Lactic acid (DB04398)••••••••••••
Prophylaxis ofPneumocystis jirovecii pneumonia••••••••••••••••••• •• ••• •• •••• •••••••• •• •••••••••••• •••••••• •••••••••• ••• ••••••••• •••••••••• •••• •••••••••• ••••• • •••••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Fluorescein sodium is used extensively as a diagnostic tool in the field of ophthalmology. Fluorescein is a fluorescent compound or fluorophore having a maximum absorbance of 494 m and an emission maximum of 521 nm. The yellowish-green fluorescence of the compound can be used to demarcate the vascular area under observation, distinguishing it from adjacent areas. It is applied topically in the form of a drop or it can be injected intravenously to produce a fluorescein angiogram. Topical fluorescein is a useful tool in the diagnosis of corneal abrasions, corneal ulcers, herpetic corneal infections, and dry eye. Fluorescein angiography is used to diagnose and categorize macular degeneration, diabetic retinopathy, inflammatory intraocular conditions, and intraocular tumors.

TargetActionsOrganism
NIg kappa chain V-II region RPMI 6410
other
Humans
NDNA
other
Humans
Absorption

Rapidly distributed

Volume of distribution
  • 0.5 L/kg
Protein binding

85%

Metabolism
Not Available
Route of elimination

Fluorescein and its metabolites are mainly eliminated via renal excretion.

Half-life

Not Available

Clearance
  • renal cl=1.75 mL/min/kg [After IV administration]
  • hepatic cl=1.50 mL/min/kg [After IV administration]
Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetazolamideThe excretion of Fluorescein can be decreased when combined with Acetazolamide.
Acetylsalicylic acidThe excretion of Fluorescein can be decreased when combined with Acetylsalicylic acid.
AcyclovirThe excretion of Fluorescein can be decreased when combined with Acyclovir.
Adefovir dipivoxilThe excretion of Adefovir dipivoxil can be decreased when combined with Fluorescein.
Aminohippuric acidThe excretion of Fluorescein can be decreased when combined with Aminohippuric acid.
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Fluorescein sodium93X55PE38X518-47-8NJDNXYGOVLYJHP-UHFFFAOYSA-L
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Ak-fluorInjection100 mg/1mLIntravenousA-S Medication Solutions2008-10-01Not applicableUS flag
Ak-fluorInjection250 mg/1mLIntravenousAkorn2008-10-01Not applicableUS flag
Ak-fluorInjection100 mg/1mLIntravenousAkorn2008-10-01Not applicableUS flag
AngiofluorInjection, solution250 mg/1mLIntravenousAlliance Inj LLC2000-12-012012-02-29US flag
Angiofluor LiteInjection, solution100 mg/1mLIntravenousAlliance Inj LLC2001-10-012012-02-29US flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
FluoresceinInjection250 mg/1mLIntravenousNexus Pharmaceuticals LLC2023-10-24Not applicableUS flag
FluoresceinInjection500 mg/1mLIntravenousNexus Pharmaceuticals LLC2023-10-24Not applicableUS flag
Odan-fluoresceinLiquid250 mg / mLIntravenousOdan Laboratories Ltd1985-12-31Not applicableCanada flag
Odan-fluoresceinSolution100 mg / mLIntravenousOdan Laboratories Ltd1984-12-31Not applicableCanada flag
Odan-fluoretsStrip1 mgOphthalmicOdan Laboratories Ltd1986-12-31Not applicableCanada flag
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
FLUORESCEIN NOVARTIS (100 MG/ML)Injection, solution100 mg/1mlOphthalmicบริษัท ซิลลิค ฟาร์มา จำกัด2015-08-31Not applicableThailand flag
FLUORETS STERILE OPHTHALMIC STRIP 1 mgStrip1 mgOphthalmicBAUSCH & LOMB (SINGAPORE) PRIVATE LIMITED1990-05-04Not applicableSingapore flag
MINIMS FLUORESCEIN SODIUM EYE DROPS 2% w/vSolution2 % w/vOphthalmicBAUSCH & LOMB (SINGAPORE) PRIVATE LIMITED1990-05-04Not applicableSingapore flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
AltafluorFluorescein sodium (2.5 mg/1mL) + Oxybuprocaine hydrochloride (4 mg/1mL)SolutionOphthalmicAltaire Pharmaceuticals Inc.2018-03-01Not applicableUS flag
AltafluorFluorescein sodium (2.5 mg/1mL) + Oxybuprocaine hydrochloride (4 mg/1mL)SolutionOphthalmicAltaire Pharmaceuticals Inc.2017-01-012018-04-19US flag
Fluorescein Sodium & Benoxinate Hydrochloride Ophthalmic Solution, USPFluorescein sodium (0.25 %) + Oxybuprocaine hydrochloride (0.4 %)SolutionOphthalmicBausch & Lomb Inc1998-10-27Not applicableCanada flag
Fluorescein Sodium and Benoxinate HydrochlorideFluorescein sodium (2.6 mg/1mL) + Oxybuprocaine hydrochloride (4.4 mg/1mL)Solution / dropsOphthalmicBausch & Lomb Americas Inc.2020-03-20Not applicableUS flag
Fluorescein Sodium and Benoxinate HydrochlorideFluorescein sodium (2.6 mg/1mL) + Oxybuprocaine hydrochloride (4.4 mg/1mL)Solution / dropsOphthalmicBausch & Lomb Incorporated2020-03-20Not applicableUS flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
AngiofluorFluorescein sodium (250 mg/1mL)Injection, solutionIntravenousAlliance Inj LLC2000-12-012012-02-29US flag
Angiofluor LiteFluorescein sodium (100 mg/1mL)Injection, solutionIntravenousAlliance Inj LLC2001-10-012012-02-29US flag
Angiofluor LiteFluorescein sodium (250 mg/1mL)Injection, solutionIntravenousAlliance Inj LLC2002-03-012012-02-29US flag
BioGloFluorescein sodium (1 mg/1mg)StripOphthalmicHUB Pharmaceuticals, Inc.2012-04-01Not applicableUS flag
BioGloFluorescein sodium (1 mg/1mg)StripOphthalmicREMEDYREPACK INC.2014-08-042017-06-24US flag

Categories

ATC Codes
S01JA01 — FluoresceinS01JA51 — Fluorescein, combinations
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as xanthenes. These are polycyclic aromatic compounds containing a xanthene moiety, which consists of two benzene rings joined to each other by a pyran ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzopyrans
Sub Class
1-benzopyrans
Direct Parent
Xanthenes
Alternative Parents
Diarylethers / Phthalides / Benzofuranones / Isobenzofurans / 1-hydroxy-2-unsubstituted benzenoids / Lactones / Carboxylic acid esters / Oxacyclic compounds / Monocarboxylic acids and derivatives / Organic oxides
show 1 more
Substituents
1-hydroxy-2-unsubstituted benzenoid / Aromatic heteropolycyclic compound / Benzenoid / Benzofuranone / Carboxylic acid derivative / Carboxylic acid ester / Diaryl ether / Ether / Hydrocarbon derivative / Isobenzofuran
show 10 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
xanthene dye, polyphenol, gamma-lactone (CHEBI:31624)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
TPY09G7XIR
CAS number
2321-07-5
InChI Key
GNBHRKFJIUUOQI-UHFFFAOYSA-N
InChI
InChI=1S/C20H12O5/c21-11-5-7-15-17(9-11)24-18-10-12(22)6-8-16(18)20(15)14-4-2-1-3-13(14)19(23)25-20/h1-10,21-22H
IUPAC Name
3',6'-dihydroxy-3H-spiro[2-benzofuran-1,9'-xanthen]-3-one
SMILES
OC1=CC=C2C(OC3=CC(O)=CC=C3C22OC(=O)C3=C2C=CC=C3)=C1

References

Synthesis Reference

Richard T. Dean, Conrad P. Dorn, Jr., Tsung-Ying Shen, "Fluorescein esters and ethers and the preparation thereof." U.S. Patent US4304720, issued January, 1972.

US4304720
General References
  1. Noga EJ, Udomkusonsri P: Fluorescein: a rapid, sensitive, nonlethal method for detecting skin ulceration in fish. Vet Pathol. 2002 Nov;39(6):726-31. [Article]
Human Metabolome Database
HMDB0014831
KEGG Drug
D01261
PubChem Compound
16850
PubChem Substance
46504703
ChemSpider
15968
BindingDB
50237588
RxNav
25138
ChEBI
31624
ChEMBL
CHEMBL1057
ZINC
ZINC000003860453
PharmGKB
PA164746009
PDBe Ligand
FLU
RxList
RxList Drug Page
Wikipedia
Fluorescein
MSDS
Download (73 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedDiagnosticUreteral Patency1
4RecruitingDiagnosticRetinal Diseases1
4SuspendedDiagnosticFluorescein angiography1
4TerminatedTreatmentAdult Intracranial Neoplasm / Vascular: Intracranial1
4Unknown StatusDiagnosticGastric Intestinal Metaplasia1

Pharmacoeconomics

Manufacturers
  • Novartis pharmaceuticals corp
  • Alcon inc
Packagers
  • Accutome Inc.
  • Akorn Inc.
  • Alcon Laboratories
  • Altaire Pharmaceuticals
  • Amend
  • Amphastar Pharmaceuticals
  • Bausch & Lomb Inc.
  • Cardinal Health
  • Conta Care Ophthalmics and Diagnostics
  • Deca Pharmaceuticals LLC
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Eye Care and Cure Corp.
  • Eye Supply Usa Inc.
  • HUB Pharmaceuticals
  • Nomax Inc.
  • Ocusoft
  • OMJ Pharmaceuticals
  • Physicians Total Care Inc.
  • Southwood Pharmaceuticals
  • Taylor Pharmaceuticals
  • Wilson Ophthalmic Corp.
Dosage Forms
FormRouteStrength
InjectionIntravenous100 mg/1mL
InjectionIntravenous250 mg/1mL
StripOphthalmic1 mg/1mg
StripOphthalmic0.12 mg/1
Injection, solutionOphthalmic
InjectionIntravenous500 mg/1mL
SolutionIntravenous250 mg / mL
Solution / dropsOphthalmic
Injection, solutionIntravenous100 mg/1mL
Injection, solutionIntravenous250 mg/1mL
Injection, solutionIntravenous0.5 g/5ml
SolutionConjunctival; Ophthalmic250 mg
SolutionIntravenous100 mg
Injection, solutionIntravenous1 G/5ML
Injection, solutionOphthalmic100 mg/1mL
SolutionIntravenous10 %
Injection, solutionOphthalmic10 %
LiquidParenteral25 %
Injection, solutionIntravenous
StripOphthalmic1 mg
Solution / dropsOphthalmic
LiquidOphthalmic
SolutionOphthalmic
StripOphthalmic1.0 mg/1
LiquidIntravenous25 %
StripOphthalmic0.6 mg/1
StripOphthalmic1 mg/1
Solution / dropsOphthalmic2 % w/v
SolutionOphthalmic2 % w/v
Solution / dropsOphthalmic; Topical
Injection, solutionIntravenous500 mg/5ml
LiquidIntravenous250 mg / mL
SolutionIntravenous100 mg / mL
Prices
Unit descriptionCostUnit
Fluorescein 2% droptainer12.0USD ml
Fluorescite 10% ampul5.99USD ml
Fluorescein lite 25% vial4.29USD ml
Ak-fluor 25% vial3.9USD ml
Fluorescein sodium 25% vial2.4USD ml
Fluorescein lite 10% vial1.72USD ml
Ak-fluor 10% vial1.56USD ml
Fluorescein sodium 10% vial0.96USD ml
Fluorescein powder0.08USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US10293047No2019-05-212037-11-15US flag
US10632197No2020-04-282037-11-15US flag
US10842872No2020-11-242037-11-15US flag

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)315 dec °CPhysProp
water solubility600 mg/mL (sodium salt)Not Available
logP3.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0255 mg/mLALOGPS
logP2.64ALOGPS
logP3.88Chemaxon
logS-4.1ALOGPS
pKa (Strongest Acidic)8.72Chemaxon
pKa (Strongest Basic)-3.7Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area75.99 Å2Chemaxon
Rotatable Bond Count0Chemaxon
Refractivity91.22 m3·mol-1Chemaxon
Polarizability33.14 Å3Chemaxon
Number of Rings5Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9542
Blood Brain Barrier+0.8803
Caco-2 permeable-0.8076
P-glycoprotein substrateSubstrate0.5063
P-glycoprotein inhibitor INon-inhibitor0.9612
P-glycoprotein inhibitor IINon-inhibitor0.9393
Renal organic cation transporterNon-inhibitor0.8702
CYP450 2C9 substrateNon-substrate0.8032
CYP450 2D6 substrateNon-substrate0.8972
CYP450 3A4 substrateNon-substrate0.6669
CYP450 1A2 substrateNon-inhibitor0.6827
CYP450 2C9 inhibitorInhibitor0.7325
CYP450 2D6 inhibitorNon-inhibitor0.8381
CYP450 2C19 inhibitorNon-inhibitor0.7311
CYP450 3A4 inhibitorInhibitor0.5166
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7479
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9437
BiodegradationNot ready biodegradable0.9431
Rat acute toxicity2.7602 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9805
hERG inhibition (predictor II)Non-inhibitor0.9481
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-MS (2 TMS)GC-MSsplash10-001i-1353900000-611445d6ab5246bd851e
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-004i-0293000000-5c35ecc919b17d5620ee
GC-MS Spectrum - EI-BGC-MSsplash10-000i-2290000000-eaff9e9aba714ba94d70
GC-MS Spectrum - EI-BGC-MSsplash10-000i-0090000000-074ba8ce3e0f48eac1d4
GC-MS Spectrum - GC-MSGC-MSsplash10-001i-1353900000-611445d6ab5246bd851e
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-001i-0009000000-ed0af5dab5a4bf01ae8f
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0019-0097000000-5521ade7b0fec9fd07c5
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-001i-0009000000-4cd93bbb46b61a14526c
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-000i-0093000000-93cfbf235912243bb1fd
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0550-0095000000-1009c9cc8319236853aa
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-000g-6090000000-4628f0bc627706680427
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-187.9563005
predicted
DarkChem Lite v0.1.0
[M-H]-176.1639455
predicted
DarkChem Lite v0.1.0
[M-H]-188.0374005
predicted
DarkChem Lite v0.1.0
[M-H]-178.7641
predicted
DeepCCS 1.0 (2019)
[M+H]+188.0805005
predicted
DarkChem Lite v0.1.0
[M+H]+178.0169652
predicted
DarkChem Lite v0.1.0
[M+H]+188.5183005
predicted
DarkChem Lite v0.1.0
[M+H]+181.1221
predicted
DeepCCS 1.0 (2019)
[M+Na]+188.5961005
predicted
DarkChem Lite v0.1.0
[M+Na]+191.7176545
predicted
DarkChem Lite v0.1.0
[M+Na]+188.8091005
predicted
DarkChem Lite v0.1.0
[M+Na]+188.00163
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Other
General Function
Antigen binding
Specific Function
Not Available
Gene Name
Not Available
Uniprot ID
P06310
Uniprot Name
Ig kappa chain V-II region RPMI 6410
Molecular Weight
14706.62 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
Kind
Nucleotide
Organism
Humans
Pharmacological action
No
Actions
Other
DNA is the molecule of heredity, as it is responsible for the genetic propagation of most inherited traits. It is a polynucleic acid that carries genetic information on cell growth, division, and function. DNA consists of two long strands of nucleotides twisted into a double helix and held together by hydrogen bonds. The sequence of nucleotides determines hereditary characteristics. Each strand serves as the template for subsequent DNA replication and as a template for mRNA production, leading to protein synthesis via ribosomes.
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
  3. Estevez-Torres A, Gosse C, Le Saux T, Allemand JF, Croquette V, Berthoumieux H, Lemarchand A, Jullien L: Fourier analysis to measure diffusion coefficients and resolve mixtures on a continuous electrophoresis chip. Anal Chem. 2007 Nov 1;79(21):8222-31. Epub 2007 Sep 25. [Article]
  4. Huang YM, Qi YJ, Zhu YL, Tong DY, Wu XY: [Polymorphism of 7 Y-STR loci in Chinese populations by multiplex PCR genotyping using fluorescein-labeled primers]. Yi Chuan. 2007 Oct;29(10):1214-22. [Article]
  5. Pennathur S, Baldessari F, Santiago JG, Kattah MG, Steinman JB, Utz PJ: Free-solution oligonucleotide separation in nanoscale channels. Anal Chem. 2007 Nov 1;79(21):8316-22. Epub 2007 Sep 21. [Article]

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Curator comments
Substrate profile was investigated in vitro using CHO and HEK293 cells.
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Lu R, Chan BS, Schuster VL: Cloning of the human kidney PAH transporter: narrow substrate specificity and regulation by protein kinase C. Am J Physiol. 1999 Feb;276(2 Pt 2):F295-303. [Article]
  2. VanWert AL, Gionfriddo MR, Sweet DH: Organic anion transporters: discovery, pharmacology, regulation and roles in pathophysiology. Biopharm Drug Dispos. 2010 Jan;31(1):1-71. doi: 10.1002/bdd.693. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Transporter activity
Specific Function
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotre...
Gene Name
ABCC1
Uniprot ID
P33527
Uniprot Name
Multidrug resistance-associated protein 1
Molecular Weight
171589.5 Da
References
  1. Sun H, Johnson DR, Finch RA, Sartorelli AC, Miller DW, Elmquist WF: Transport of fluorescein in MDCKII-MRP1 transfected cells and mrp1-knockout mice. Biochem Biophys Res Commun. 2001 Jun 22;284(4):863-9. [Article]

Drug created at June 13, 2005 13:24 / Updated at March 18, 2024 16:48